Please ensure Javascript is enabled for purposes of website accessibility Recalculating Route: At the Table with BNY
lu
en
institutional
institutional
false
true
Gathering data
Disclaimer Not Available

Recalculating route

At the Table with BNY

Recalculating route

BNY has been at the center of global finance for more than 240 years. Since our founding, we’ve put our expertise and breadth to work in helping clients succeed. Today, as markets evolve amid shifting policy, technological transformation and structural realignment, our mission remains the same: deliver actionable insights and lasting outcomes.

Our commitment to insight and perspectives comes to life through our investment and markets leaders who gather quarterly to debate the key issues shaping markets today. We draw on the firm’s global reach and intellectual depth to produce forward-looking perspectives that help investors navigate complexity with confidence.

This quarter, conversations centered on fixed income. We dissected how resilient growth, shifting rate expectations, and diverging global monetary policies are reshaping opportunities across credit and sovereign markets. In particular, the Federal Reserve’s (Fed’s) recent rate cuts – seen more as insurance than stimulus – fueled debate on whether easing can extend the cycle without reigniting inflation.

We also looked at the global economy and how it continues to balance growth with policy recalibration. In the U.S., most of the uncertainty from tariffs has likely passed, but residual effects remain, partly offset by lower corporate tax rates. The Fed will follow the direction of travel signaled at its October meeting by easing policy further. Globally, policy easing is expected to support a reacceleration into 2026.

In markets, we expect corporate profitability to remain strong as companies continue to find success managing margins. The sustainability of the growth in artificial intelligence (AI) continues to be a central topic of discussion. We think cash flow strength in the tech sector sets this cycle apart from the dot-com era. Earnings growth is also broadening beyond big tech and rate relief should aid smaller, more levered companies.

Meanwhile, the housing market remains constrained, but lower rates should ease the imbalance and early signs of a rebound are becoming more visible. Still, with fiscal dynamics taking greater precedence and inflation likely to remain above target, return of capital – not just a return on capital – remains a central theme.

Through this report, we offer you a seat at our table where clarity comes from disciplined analysis and diverse perspectives. We offer insights across asset classes, regions and policy regimes, turning global complexity into actionable opportunity.

Eric Hundahl
Head of BNY Investment Institute1
BNY Advisors

1 BNY Investment Institute consists of BNY Advisors’ macroeconomic research, asset allocation, manager research and operational due diligence teams.

GU-691 Exp: 30 June 2026

RELATED CONTENT
Healthy correction?
Article | Macroeconomic

After climbing 17% year to date through late October, the S&P 500 declined 5% through November 20. We believe the market was due for a healthy correction. While further downside is possible, it would not concern us.

Healthy correction?
Chart of the week | Macroeconomic

After climbing 17% year to date through late October, the S&P 500 declined 5% through November 20. We believe the market was due for a healthy correction. While further downside is possible, it would not concern us.

The strategic bond conundrum
Article | Fixed Income

For advisers, focused on a breadth of client needs, there isn’t enough time in their day to navigate the complex nuances of bond markets. This explains the popularity of strategic bond funds. They can hand decision-making to an expert, with a flexible mandate to roam across bond markets, finding the best opportunities. However, this flexibility means evaluation is difficult, and advisers aren’t always getting the outcomes they expect.

Novo Nordisk: rethinking the playbook
Article | Equities

Direct-to-client (DTC) health platforms and personalized compounded treatments may become standard practice in the rapidly evolving obesity treatment market. Walter Scott investment analyst Dr Oriana Beaumont believes that Novo Nordisk’s recent changes will help position them to effectively compete in this exciting and vast market.

Gathering data
Disclaimer Not Available

This is a marketing communication